Part of the Oncology Commons
2019
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma., Kimmie Ng, Andrew Hendifar, Alexander Starodub MD, Jorge Chaves, Yingsi Yang, Brian Koh, David Barbie, William C Hahn, Charles S Fuchs
PCI Publications and Projects
